Op-ed: 5 un­set­tled is­sues a Califf-run FDA will need to tack­le in 2022 and be­yond

As Rob Califf like­ly makes his re­turn as FDA com­mis­sion­er next month, his con­fir­ma­tion hear­ing yes­ter­day of­fered a peek in­to some of the larg­er ob­sta­cles he’s go­ing to face in the com­ing months and years.

The pan­dem­ic isn’t go­ing away any­time soon with Omi­cron, and some vac­cines and ther­a­peu­tics may need to be tweaked or pulled from the mar­ket en­tire­ly as they prove to be in­ef­fec­tive against the new vari­ant. The FDA, mean­while, needs to get back on even foot­ing with some longer-term di­rec­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER